DUBLIN, April 28 /PRNewswire-FirstCall/ -- Shire plc , the global specialty biopharmaceutical company, announces that at its Annual General Meeting today, all resolutions contained in the notice of meeting were duly passed and the results of the poll are as follows:
** A vote “withheld” is not a vote in law and is not counted in the calculation of the votes “for” or “against” a resolution.
Two copies of all resolutions passed, other than resolutions concerning ordinary business, will shortly be submitted to the UK Listing Authority and will be available for inspection at the UK Listing Authority’s Document Viewing Facility, which is situated at the Financial Services Authority, 25 The North Colonnade, Canary Wharf, London E14 5HS.
Notes to Editors
SHIRE PLC
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: http://www.shire.com.
CONTACT: For further information please contact: Shire plc: Tony Guthrie,
Deputy Company Secretary, +44(0)1256-894746. Investor Relations: Clea
Rosenfeld (Rest of the World), +44-1256-894-160; Eric Rojas (North
America), +1-617-551-9715. Media: Jessica Mann (Rest of the World),
+44-1256-894-280; Matthew Cabrey (North America), +1-484-595-8248; Jessica
Cotrone (North America), +1-617-613-4640
